Lung Squamous Cell Carcinoma — Trials

Lung Squamous Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

141 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 37
Recruiting: 19
Ph III recruiting: 1
Growth YoY: —
Industry share: 46%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (24)

clinicaltrialsPublishedShowing 1–14 of 14 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03965689	Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	active not recruiting	Phase 2	27	National Cancer Institute (NCI)NIH	1	Sep 22, 2026	clinicaltrials
NCT04216316	Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer	active not recruiting	Phase 1 / Phase 2	12	National Cancer Institute (NCI)